BioCentury | Aug 17, 2015
Emerging Company Profile

Checkpoint and mate

...at Coley Pharmaceutical Group Inc. , a company he co-founded that Pfizer Inc. acquired in 2008. He said Coley...
BioCentury | May 18, 2015
Emerging Company Profile

RIG-ged against cancer

...was SVP of European Operations at Coley, which Pfizer Inc. acquired in 2008. But while Coley...
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

...saw two acquisitions of TLR companies: Corixa Corp. by GlaxoSmithKline plc for $300 million, and Coley...
...abandoned development of the prodrug of the TLR7 agonist isatoribine. Also in 2007, Pfizer and Coley's...
...of efficacy. Christelle Perros-Huguet, SVP and CSO of Pfizer's inflammation and remodeling research unit, said Coley's...
BioCentury | Jan 23, 2012
Emerging Company Profile

RaNA: Specific in epigenetics

...repressor that methylates histone H3. Arthur Krieg, who was a founder and former CSO of Coley Pharmaceutical Group Inc....
...CEO after approaching Formela about spinning out some science from Pfizer Inc. , which acquired Coley...
BioCentury | Sep 6, 2010
Company News

Emergent BioSolutions, National Institutes of Health infectious news

...approved in the U.S. to prevent anthrax. Emergent has a non-exclusive license to VaxImmune from Coley Pharmaceutical Group Inc....
BioCentury | Oct 1, 2009
Tools & Techniques

Silent but deadly delivery

...advance this approach toward human clinical trials." Krieg was a founder and former CSO of Coley...
BioCentury | Aug 10, 2009
Company News

Molecular Insight management update

...Cancer Hired: Charles Abdalian as VP of finance and CFO, formerly SVP and CFO at Coley...
BioCentury | May 4, 2009
Product Development

Adjuvant Technologies

...that inhibit T regulatory cells Pfizer Inc. (NYSE:PFE) Oligodeoxynucleotide adjuvant technology that agonizes TLR9; from Coley...
BioCentury | May 4, 2009
Product Development

Opportunity in Crisis

...pharma's Research Technology Center and former CSO and co-founder of Coley Pharmaceutical Group. Pfizer acquired Coley...
...kind of safety data available for the adjuvants," he noted. Prior to the Pfizer acquisition, Coley...
...but with the same level of severity, in individuals who received CPG 7909. In 2002, Coley...
BioCentury | Jan 19, 2009
Company News

Cequent management update

...Autoimmune Hired: Ted Hibben as CBO, formerly VP of business development and alliance management at Coley Pharmaceutical Group Inc....
Items per page:
1 - 10 of 186
BioCentury | Aug 17, 2015
Emerging Company Profile

Checkpoint and mate

...at Coley Pharmaceutical Group Inc. , a company he co-founded that Pfizer Inc. acquired in 2008. He said Coley...
BioCentury | May 18, 2015
Emerging Company Profile

RIG-ged against cancer

...was SVP of European Operations at Coley, which Pfizer Inc. acquired in 2008. But while Coley...
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

...saw two acquisitions of TLR companies: Corixa Corp. by GlaxoSmithKline plc for $300 million, and Coley...
...abandoned development of the prodrug of the TLR7 agonist isatoribine. Also in 2007, Pfizer and Coley's...
...of efficacy. Christelle Perros-Huguet, SVP and CSO of Pfizer's inflammation and remodeling research unit, said Coley's...
BioCentury | Jan 23, 2012
Emerging Company Profile

RaNA: Specific in epigenetics

...repressor that methylates histone H3. Arthur Krieg, who was a founder and former CSO of Coley Pharmaceutical Group Inc....
...CEO after approaching Formela about spinning out some science from Pfizer Inc. , which acquired Coley...
BioCentury | Sep 6, 2010
Company News

Emergent BioSolutions, National Institutes of Health infectious news

...approved in the U.S. to prevent anthrax. Emergent has a non-exclusive license to VaxImmune from Coley Pharmaceutical Group Inc....
BioCentury | Oct 1, 2009
Tools & Techniques

Silent but deadly delivery

...advance this approach toward human clinical trials." Krieg was a founder and former CSO of Coley...
BioCentury | Aug 10, 2009
Company News

Molecular Insight management update

...Cancer Hired: Charles Abdalian as VP of finance and CFO, formerly SVP and CFO at Coley...
BioCentury | May 4, 2009
Product Development

Adjuvant Technologies

...that inhibit T regulatory cells Pfizer Inc. (NYSE:PFE) Oligodeoxynucleotide adjuvant technology that agonizes TLR9; from Coley...
BioCentury | May 4, 2009
Product Development

Opportunity in Crisis

...pharma's Research Technology Center and former CSO and co-founder of Coley Pharmaceutical Group. Pfizer acquired Coley...
...kind of safety data available for the adjuvants," he noted. Prior to the Pfizer acquisition, Coley...
...but with the same level of severity, in individuals who received CPG 7909. In 2002, Coley...
BioCentury | Jan 19, 2009
Company News

Cequent management update

...Autoimmune Hired: Ted Hibben as CBO, formerly VP of business development and alliance management at Coley Pharmaceutical Group Inc....
Items per page:
1 - 10 of 186